MX9700041A - Vitronectin receptor antagonists. - Google Patents

Vitronectin receptor antagonists.

Info

Publication number
MX9700041A
MX9700041A MX9700041A MX9700041A MX9700041A MX 9700041 A MX9700041 A MX 9700041A MX 9700041 A MX9700041 A MX 9700041A MX 9700041 A MX9700041 A MX 9700041A MX 9700041 A MX9700041 A MX 9700041A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
vitronectin receptor
compounds
vitronectin
osteoporosis
Prior art date
Application number
MX9700041A
Other languages
Spanish (es)
Inventor
Fadia El-Fehail Ali
William Bondinell
William Francis Huffman
M Amparo Lago
Richard Mcculloch Keenan
Chet Kwon
William Henry Miller
Thomas Nguyen
Dennis T Takata
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9700041A publication Critical patent/MX9700041A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. These compounds comprise a fibrinogen receptor antagonist template linked to a heterocyclic moiety.
MX9700041A 1994-06-29 1995-06-29 Vitronectin receptor antagonists. MX9700041A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26769594A 1994-06-29 1994-06-29
US42893395A 1995-04-25 1995-04-25
PCT/US1995/008306 WO1996000730A1 (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
MX9700041A true MX9700041A (en) 1997-04-30

Family

ID=26952569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700041A MX9700041A (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists.

Country Status (13)

Country Link
EP (1) EP0767792A4 (en)
JP (1) JPH10504808A (en)
CN (1) CN1156995A (en)
AU (1) AU702661B2 (en)
BR (1) BR9508178A (en)
CA (1) CA2193966A1 (en)
CZ (1) CZ382496A3 (en)
HU (1) HUT76344A (en)
MX (1) MX9700041A (en)
NO (1) NO965608L (en)
NZ (3) NZ290008A (en)
PL (1) PL318199A1 (en)
WO (1) WO1996000730A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
AU702487B2 (en) * 1995-08-30 1999-02-25 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
ATE212990T1 (en) 1996-03-20 2002-02-15 Hoechst Ag BONE RESORPTION INHIBITORS AND VITRONECTIN RECEPTOR ANTAGONISTS
DE19629816A1 (en) 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
DE19629817A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
WO1998015278A1 (en) * 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
DE19653647A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19653645A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
AU8689798A (en) * 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6228985B1 (en) 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
CN1319094A (en) * 1998-06-12 2001-10-24 研究及应用科学协会股份有限公司 Imidazolyl derivatives
HUP0103090A3 (en) * 1998-08-07 2002-12-28 Smithkline Beecham Corp Vitronectin receptor antagonist oxazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE19842415A1 (en) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CN1161340C (en) * 1998-11-30 2004-08-11 先灵公司 Benzimidazole compounds that are vitronectin receptor antagonists
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
WO2000035887A2 (en) 1998-12-18 2000-06-22 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP2002536370A (en) 1999-02-03 2002-10-29 メルク エンド カムパニー インコーポレーテッド Benzoazepine derivatives as α-V integrin receptor antagonists
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
CA2369557A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of gabaa receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
EP1165518A2 (en) * 1999-04-02 2002-01-02 Neurogen Corporation Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors
IL145732A0 (en) 1999-04-06 2002-07-25 Sankyo Co α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CO5180550A1 (en) 1999-04-19 2002-07-30 Smithkline Beecham Corp FAB I INHIBITORS
AR024158A1 (en) 1999-06-01 2002-09-04 Smithkline Beecham Corp ANTIBACTERIAL COMPOUNDS
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CA2387016C (en) 1999-10-08 2010-09-28 William H. Miller Acrylamide derivatives as fab i inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
AU2001229580A1 (en) * 2000-01-18 2001-08-14 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
FR2806082B1 (en) * 2000-03-07 2002-05-17 Adir NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2001258638A1 (en) 2000-05-26 2001-12-03 Glaxo Group Limited Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
KR20030020960A (en) 2000-08-01 2003-03-10 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Imidazolyl derivatives
AU2001288485A1 (en) * 2000-08-29 2002-03-13 Balekudru Devadas Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
FR2822463B1 (en) 2001-03-21 2004-07-30 Lipha BICYCLIC GUANIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
DK1560584T3 (en) 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitors
CN1247258C (en) 2001-04-24 2006-03-29 默克专利有限公司 Combination therapy using anti-angiogenic agents and tnfa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
FR2829765A1 (en) * 2001-09-14 2003-03-21 Lipha Use of new and known benzimidazolyl alkoxyaryl alkanoic acid derivatives for treating pathologies associated with insulin resistance or hyperglycemia
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
FR2847254B1 (en) 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
PE20040804A1 (en) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR
FR2870541B1 (en) 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20090130098A1 (en) 2006-01-18 2009-05-21 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
ES2399159T3 (en) 2007-01-18 2013-03-26 Merck Patent Gmbh Specific therapy and medication using integrin ligands for cancer treatment
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa Salts, prodrugs and polymorphs of fab i inhibitors
CA2705916C (en) 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
JP5572996B2 (en) * 2009-05-15 2014-08-20 宇部興産株式会社 Medicine containing benzazepinone compound as active ingredient
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
PL2585467T3 (en) 2010-06-24 2016-09-30 Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents
JP6122868B2 (en) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド Pyrazolo [1,5-A] pyrimidine as an antiviral agent
SG10201610166VA (en) 2012-04-17 2017-01-27 Gilead Sciences Inc Compounds and methods for antiviral treatment
IN2014KN02915A (en) 2012-06-19 2015-05-08 Debiopharm Int Sa
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
TN2018000293A1 (en) 2016-02-26 2020-01-16 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
CN108707116B (en) * 2018-07-05 2021-11-30 华侨大学 2-alkyl substituted benzimidazole derivative and preparation method thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR71915B (en) * 1979-11-27 1983-08-16 Pfizer
US4556660A (en) * 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
GB8316645D0 (en) * 1983-06-18 1983-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
FR2643903A1 (en) * 1989-03-03 1990-09-07 Union Pharma Scient Appl NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
RU1836357C (en) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine
ES2190428T3 (en) * 1991-06-28 2003-08-01 Smithkline Beecham Corp BIBLICAL FIBRINOGEN ANTAGONISTS.
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
SG63579A1 (en) * 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5863950A (en) * 1993-01-15 1999-01-26 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5300668A (en) * 1993-03-10 1994-04-05 Pfizer Inc. Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates

Also Published As

Publication number Publication date
CA2193966A1 (en) 1996-01-11
NZ329656A (en) 2000-01-28
NZ329822A (en) 2000-02-28
HUT76344A (en) 1997-08-28
EP0767792A4 (en) 2002-11-20
NZ290008A (en) 1998-08-26
JPH10504808A (en) 1998-05-12
CN1156995A (en) 1997-08-13
WO1996000730A1 (en) 1996-01-11
PL318199A1 (en) 1997-05-26
EP0767792A1 (en) 1997-04-16
NO965608D0 (en) 1996-12-27
NO965608L (en) 1997-02-27
CZ382496A3 (en) 1997-12-17
HU9603525D0 (en) 1997-02-28
BR9508178A (en) 1997-11-18
AU3001095A (en) 1996-01-25
AU702661B2 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
MX9700041A (en) Vitronectin receptor antagonists.
MX9805253A (en) Vitronectin receptor antagonists.
NZ307625A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
TR199801253T2 (en) Vitronectin receptor antagonists.
EP0488046A3 (en) Surveying machine for construction work
GB9406857D0 (en) Improvements in or relating to organic compounds
ZA917695B (en) Fibrinogen receptor antagonists
GB9405317D0 (en) Fibrinogen receptor antagonists
DE69207351D1 (en) Fibrinogen receptor antagonists
EP0673247A4 (en) Fibrinogen receptor antagonists.
EP0667773A4 (en) Fibrinogen receptor antagonists.
DE69127791D1 (en) Diazabicyclononyl derivatives as 5-HT3 receptor antagonists
MXPA03009644A (en) 1 substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists).
EP0796098A4 (en) Fibrinogen receptor antagonists
TR200000786T2 (en) Vitronectin receptor antagonist
BR9812340A (en) Vitronectin receptor antagonists
ES2182349T3 (en) ORTO-METALIZATION PROCEDURE FOR THE SYNTHESIS OF 1- (TETRAZOL-5-IL) BENCHES REPLACED IN POSITION 2.
EP0801650A4 (en) Fibrinogen receptor antagonists
ZA949291B (en) Isoxazoline compounds useful as fibrinogen receptor antagonists
EP0714295A4 (en)
KR950700252A (en) Process for preparing fibrinogen receptor antagonists
AP1534A (en) Vitronectin receptor antagonists.
GB9320799D0 (en) Fibrinogen receptor antagonists
EP0794779A4 (en) Fibrinogen receptor antagonists
GB9107063D0 (en) Drilling template for orthopaedic use